Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 1 Mental state: 1a. Average endpoint in general mental state scores (PANSS total, high=poor).
Figuras y tablas -
Analysis 1.1

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 1 Mental state: 1a. Average endpoint in general mental state scores (PANSS total, high=poor).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Notes

Louza 2004

Conjugated estrogens

7.95

7.10

21

Louza 2004

Placebo

12.89

9.68

19

Figuras y tablas -
Analysis 1.2

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 2 Mental state: 1b. Average endpoint in general mental state scores (BPRS, skewed data, high=poor).

Ir a la figura de la revisión

Study

Intervention

N

Mean

SD

Kulkarni 2001

Estrogen 100mcg

12

14.45

7.4

Kulkarni 2001

Placebo

12

15.37

5.5

Figuras y tablas -
Analysis 1.3

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 3 Mental state: 2a. Average endpoint in positive symptom scores (PANSS positive, high=poor).

Ir a la figura de la revisión

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 4 Mental state: 2b. Average endpoint in positive symptom scores ‐ 50mcg estrogen (PANSS positive, high=poor).
Figuras y tablas -
Analysis 1.4

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 4 Mental state: 2b. Average endpoint in positive symptom scores ‐ 50mcg estrogen (PANSS positive, high=poor).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Kulkarni 1996

Estrogen

22.20

23.91

11

Kulkarni 1996

Placebo

25.90

16.24

7

Figuras y tablas -
Analysis 1.5

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 5 Mental state: 2c. Average endpoint in positive symptom scores (SAPS, skewed data, high=poor).

Ir a la figura de la revisión

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 6 Mental state: 3a. Average endpoint in negative symptom scores (PANSS negative, high=poor).
Figuras y tablas -
Analysis 1.6

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 6 Mental state: 3a. Average endpoint in negative symptom scores (PANSS negative, high=poor).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Louza 2004

Conjugated estrogen

13.24

8048

21

Louza 2004

Placebo

15.79

9.46

19

Figuras y tablas -
Analysis 1.7

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 7 Mental state: 3b. Average endpoint in negative symptom scores (NSRS,skewed data, high=poor).

Ir a la figura de la revisión

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 8 Mental state: 4a. Average endpoint in psychopathology scores (PANSS general symptoms subscale, high=poor).
Figuras y tablas -
Analysis 1.8

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 8 Mental state: 4a. Average endpoint in psychopathology scores (PANSS general symptoms subscale, high=poor).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 9 Leaving the study early: up to 8 weeks.
Figuras y tablas -
Analysis 1.9

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 9 Leaving the study early: up to 8 weeks.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Abnormal Involuntary Movements Scale

Glazer 1985

Conjugated estrogens

4.60

0.55

5

Glazer 1985

Placebo

5.80

3.35

5

Simpson & Angus Extrapyramidal Rating Scale

Louza 2004

Conjugated estrogens

1.29

2.05

21

Louza 2004

Placebo

1.89

3.31

19

Figuras y tablas -
Analysis 1.10

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 10 Adverse effects: 1. Average endpoint movement disorder scores (skewed data, high=poor).

Ir a la figura de la revisión

Study

Intervention

Mean

SD

N

Louza 2004

Conjugated estrogens

1.09

2.30

21

Louza 2004

Placebo

3.05

4.08

19

Figuras y tablas -
Analysis 1.11

Comparison 1 ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 11 Adverse effects: 2. Average endpoint adverse side‐effect scores (UKU, skewed data, high=poor).

Ir a la figura de la revisión

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 1 Mental state: Average endpoint general mental state scores (PANSS, high= poor).
Figuras y tablas -
Analysis 2.1

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 1 Mental state: Average endpoint general mental state scores (PANSS, high= poor).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 2 Leaving the study early ‐ up to 6 months.
Figuras y tablas -
Analysis 2.2

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 2 Leaving the study early ‐ up to 6 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 3 Cognitive functioning: Average endpoint specific aspects of cognitive functioning.
Figuras y tablas -
Analysis 2.3

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 3 Cognitive functioning: Average endpoint specific aspects of cognitive functioning.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Component tests

Interventions

Mean

SD

N

Motor dexterity (Grooved Pegboard, high=good)

Good 1999

Dominant hand

Estrogen plus progesterone

149.6

167.2

5

Good 1999

Placebo

189.0

96.8

3

Good 1999

Non‐dominant hand

estrogen plus progesterone

144.4

127.7

5

Good 1999

Placebo

184.7

99.9

3

Good 1999

Good 1999

Design fluency (Design Fluency Test, high=good)

Good 1999

Design fluency free

Estrogen plus progesterone

15.8

8.2

5

Good 1999

Placebo

11.3

9.0

4

Good 1999

Design fluency fixed

Estrogen plus placebo

11.4

6.1

5

Good 1999

Placebo

7.0

2.9

4

Good 1999

Good 1999

Verbal Fluency (COWA,high=good)

Good 1999

Estrogen plus progesterone

33.6

6.9

5

Good 1999

Placebo

16.8

11.0

4

Good 1999

Good 1999

Good 1999

Good 1999

Auditory‐Verbal Learning Test (AVLT trial, high=good)

Good 1999

AVLT trial 1

Estrogen plus progesterone

7.2

5.0

5

Good 1999

Placebo

2.8

2.2

4

Good 1999

AVLT trial 1‐5

Estrogen plus progesterone

45.4

24.8

5

Good 1999

Placebo

24.5

15.0

4

Good 1999

AVLT delayed

Estrogen plus placebo

8.6

5.9

5

Good 1999

Placebo

3.8

2.9

4

Smell identification (UPSIT, high=good)

Good 1999

Estrogen plus progesterone

31.2

7.2

5

Good 1999

Placebo

16.3

11.7

4

Good 1999

Good 1999

Good 1999

Good 1999

Smell sensitivity (Acuity, high=good)

Good 1999

Estrogen plus progesterone

8.4

1.9

5

Good 1999

Placebo

5.8

3.8

4

Good 1999

Good 1999

Good 1999

Good 1999

Figuras y tablas -
Analysis 2.4

Comparison 2 ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT, Outcome 4 Cognitive functioning: Average endpoint specific aspects of cognitive functioning.

Ir a la figura de la revisión
Comparison 1. ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mental state: 1a. Average endpoint in general mental state scores (PANSS total, high=poor) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 100 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐2.26 [‐15.44, 10.92]

1.2 50 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐4.62 [‐14.60, 5.36]

2 Mental state: 1b. Average endpoint in general mental state scores (BPRS, skewed data, high=poor) Show forest plot

Other data

No numeric data

3 Mental state: 2a. Average endpoint in positive symptom scores (PANSS positive, high=poor) Show forest plot

Other data

No numeric data

4 Mental state: 2b. Average endpoint in positive symptom scores ‐ 50mcg estrogen (PANSS positive, high=poor) Show forest plot

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.37 [‐5.36, 4.62]

5 Mental state: 2c. Average endpoint in positive symptom scores (SAPS, skewed data, high=poor) Show forest plot

Other data

No numeric data

6 Mental state: 3a. Average endpoint in negative symptom scores (PANSS negative, high=poor) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

6.1 100 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.51 [‐3.65, 2.63]

6.2 50 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐2.21 [‐4.73, 0.31]

7 Mental state: 3b. Average endpoint in negative symptom scores (NSRS,skewed data, high=poor) Show forest plot

Other data

No numeric data

8 Mental state: 4a. Average endpoint in psychopathology scores (PANSS general symptoms subscale, high=poor) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

8.1 100 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐0.83 [‐7.88, 6.22]

8.2 50 mcg estrogen

1

24

Mean Difference (IV, Fixed, 95% CI)

‐2.04 [‐7.01, 2.93]

9 Leaving the study early: up to 8 weeks Show forest plot

4

96

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.15, 6.07]

10 Adverse effects: 1. Average endpoint movement disorder scores (skewed data, high=poor) Show forest plot

Other data

No numeric data

10.1 Abnormal Involuntary Movements Scale

Other data

No numeric data

10.2 Simpson & Angus Extrapyramidal Rating Scale

Other data

No numeric data

11 Adverse effects: 2. Average endpoint adverse side‐effect scores (UKU, skewed data, high=poor) Show forest plot

Other data

No numeric data
Figuras y tablas -
Comparison 1. ESTROGEN (mostly 100 mcg) + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT
Ir a la tabla de la revisión
Comparison 2. ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Mental state: Average endpoint general mental state scores (PANSS, high= poor) Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 PANSS postive symptom scores

1

9

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐10.52, 6.52]

1.2 PANSS negative symptom scores

1

9

Mean Difference (IV, Fixed, 95% CI)

‐9.0 [‐17.11, ‐0.89]

1.3 PANSS psychopathology scores

1

9

Mean Difference (IV, Fixed, 95% CI)

‐14.30 [‐29.31, 0.71]

1.4 PANSS total scores

1

9

Mean Difference (IV, Fixed, 95% CI)

‐25.30 [‐50.74, 0.14]

2 Leaving the study early ‐ up to 6 months Show forest plot

1

10

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.02, 6.65]

3 Cognitive functioning: Average endpoint specific aspects of cognitive functioning Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

3.1 Visual Retention Test (BVRT total, high=good)

1

8

Mean Difference (IV, Fixed, 95% CI)

‐3.5 [‐5.73, ‐1.27]

3.2 Visual Retention Test (BVRT errors, high=poor)

1

8

Mean Difference (IV, Fixed, 95% CI)

‐12.0 [‐17.62, ‐6.38]

3.3 Motor speed (Finger tapping dominant hand, high=good)

1

9

Mean Difference (IV, Fixed, 95% CI)

‐5.10 [‐19.22, 9.02]

3.4 Motor speed (Finger tapping non‐dominant hand, high=good)

1

9

Mean Difference (IV, Fixed, 95% CI)

‐7.70 [‐23.72, 8.32]

4 Cognitive functioning: Average endpoint specific aspects of cognitive functioning Show forest plot

Other data

No numeric data

4.1 Motor dexterity (Grooved Pegboard, high=good)

Other data

No numeric data

4.2 Design fluency (Design Fluency Test, high=good)

Other data

No numeric data

4.3 Verbal Fluency (COWA,high=good)

Other data

No numeric data

4.4 Auditory‐Verbal Learning Test (AVLT trial, high=good)

Other data

No numeric data

4.5 Smell identification (UPSIT, high=good)

Other data

No numeric data

4.6 Smell sensitivity (Acuity, high=good)

Other data

No numeric data
Figuras y tablas -
Comparison 2. ESTROGEN + PROGESTERONE + STANDARD TREATMENT vs PLACEBO + STANDARD TREATMENT
Ir a la tabla de la revisión